The consensus molecular subtypes of colorectal cancer

Guinney, Justin, Dienstmann, Rodrigo, Wang, Xin, de Reyniès, Aurélien, Schlicker, Andreas, Soneson, Charlotte, Marisa, Laetitia, Roepman, Paul +32 more·2015·Nature Medicine
DOI 10.1038/nm.3967

Cited by (161)

Items 101–161 of 161

  1. Microsatellite Instability in Colorectal Cancers: Carcinogenesis, Neo-Antigens, Immuno-Resistance and Emerging Therapies
    Randrian, Violaine, Evrard, Camille, Tougeron, David · 2021 · Cancers
  2. Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4
    van den Bulk, Jitske, Verdegaal, Els M. E., Ruano, Dina, Ijsselsteijn, Marieke E., Visser, Marten, van der Breggen, Ruud, Duhen, Thomas, van der Ploeg, Manon, de Vries, Natasja L., Oosting, Jan et al. · 2019 · Genome Medicine
  3. A clinically applicable gene-expression classifier reveals intrinsic and extrinsic contributions to consensus molecular subtypes in primary and metastatic colon cancer
    Piskol, Robert, Huw, Ling, Sergin, Ismail, Kljin, Christiaan, Modrusan, Zora, Kim, Doris, Kljavin, Noelyn, Tam, Rachel, Patel, Rajesh, Burton, Jeremy et al. · 2019 · Clinical Cancer Research
  4. Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in mice
    Ragusa, Simone, Prat-Luri, Borja, González-Loyola, Alejandra, Nassiri, Sina, Squadrito, Mario Leonardo, Guichard, Alan, Cavin, Sabrina, Gjorevski, Nikolce, Barras, David, Marra, Giancarlo et al. · 2020 · Journal of Clinical Investigation
  5. Methylation-Based Therapies for Colorectal Cancer
    Cervena, Klara, Siskova, Anna, Buchler, Tomas, Vodicka, Pavel, Vymetalkova, Veronika · 2020 · Cells
  6. The cellular prion protein controls the mesenchymal-like molecular subtype and predicts disease outcome in colorectal cancer
    Le Corre, Delphine, Ghazi, Alexandre, Balogoun, Ralyath, Pilati, Camilla, Aparicio, Thomas, Martin-Lannerée, Séverine, Marisa, Laetitia, Djouadi, Fatima, Poindessous, Virginie, Crozet, Carole et al. · 2019 · eBioMedicine
  7. BCL-2 system analysis identifies high-risk colorectal cancer patients
    Lindner, Andreas U, Salvucci, Manuela, Morgan, Clare, Monsefi, Naser, Resler, Alexa J, Cremona, Mattia, Curry, Sarah, Toomey, Sinead, O'Byrne, Robert, Bacon, Orna et al. · 2017 · Gut
  8. Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2
    Chang, K., Willis, J.A., Reumers, J., Taggart, M.W., San Lucas, F.A., Thirumurthi, S., Kanth, P., Delker, D.A., Hagedorn, C.H., Lynch, P.M. et al. · 2018 · Annals of Oncology
  9. Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and Survival
    Kato, Shumei, Schwaederlé, Maria C., Fanta, Paul T., Okamura, Ryosuke, Leichman, Lawrence, Lippman, Scott M., Lanman, Richard B., Raymond, Victoria M., Talasaz, AmirAli, Kurzrock, Razelle · 2019 · JCO Precision Oncology
  10. Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair Deficiency
    Cohen, Romain, Colle, Raphaël, Pudlarz, Thomas, Heran, Maximilien, Duval, Alex, Svrcek, Magali, André, Thierry · 2021 · Cancers
  11. Sessile serrated polyps and colon cancer prevention
    Rashtak, Shahrooz, Rego, Rafaela, Sweetser, Seth R., Sinicrope, Frank A. · 2017 · Cancer Prevention Research
  12. Cancer-Associated Fibroblasts: The Origin, Biological Characteristics and Role in Cancer—A Glance on Colorectal Cancer
    Fotsitzoudis, Charalampos, Koulouridi, Asimina, Messaritakis, Ippokratis, Konstantinidis, Theocharis, Gouvas, Nikolaos, Tsiaoussis, John, Souglakos, John · 2022 · Cancers
  13. Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR)
    Basile, D., Broudin, C., Emile, J.F., Falcoz, A., Pagès, F., Mineur, L., Bennouna, J., Louvet, C., Artru, P., Fratte, S. et al. · 2022 · Annals of Oncology
  14. Neoadjuvant chemotherapy affects molecular classification of colorectal tumors
    Trumpi, K, Ubink, I, Trinh, A, Djafarihamedani, M, Jongen, J M, Govaert, K M, Elias, S G, van Hooff, S R, Medema, J P, Lacle, M M et al. · 2017 · Oncogenesis
  15. Genetic Alterations of Metastatic Colorectal Cancer
    Testa, Ugo, Castelli, Germana, Pelosi, Elvira · 2020 · Biomedicines
  16. Clinical Challenges of Consensus Molecular Subtype CMS4 Colon Cancer in the Era of Precision Medicine
    Mouillet-Richard, Sophie, Cazelles, Antoine, Sroussi, Marine, Gallois, Claire, Taieb, Julien, Laurent-Puig, Pierre · 2024 · Clinical Cancer Research
  17. The role of immunotherapy in microsatellites stable metastatic colorectal cancer: State of the art and future perspectives
    Gandini, Annalice, Puglisi, Silvia, Pirrone, Chiara, Martelli, Valentino, Catalano, Fabio, Nardin, Simone, Seeber, Andreas, Puccini, Alberto, Sciallero, Stefania · 2023 · Frontiers in Oncology
  18. A tumor microenvironment-specific gene expression signature predicts chemotherapy resistance in colorectal cancer patients
    Zhu, Xiaoqiang, Tian, Xianglong, Ji, Linhua, Zhang, Xinyu, Cao, Yingying, Shen, Chaoqin, Hu, Ye, Wong, Jason W. H., Fang, Jing-Yuan, Hong, Jie et al. · 2021 · npj Precision Oncology
  19. Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression
    Napolitano, S., Matrone, N., Muddassir, A. L., Martini, G., Sorokin, A., De Falco, V., Giunta, E. F., Ciardiello, D., Martinelli, E., Belli, V. et al. · 2019 · Journal of Experimental & Clinical Cancer Research
  20. A novel diagnostic tool for selecting patients with mesenchymal-type colon cancer reveals intratumor subtype heterogeneity
    Ubink, Inge, Elias, Sjoerd G., Moelans, Cathy B., Laclé, Miangela M., van Grevenstein, Wilhelmina M. U., van Diest, Paul J., Borel Rinkes, Inne H. M., Kranenburg, Onno · 2017 · JNCI: Journal of the National Cancer Institute
  21. YAP/TAZ signalling in colorectal cancer: lessons from consensus molecular subtypes
    Mouillet-Richard, Sophie, Laurent-Puig, Pierre · 2020 · Cancers
  22. Current and emerging concepts for systemic treatment of metastatic colorectal cancer
    Steup, Christoph, Kennel, Kilian B, Neurath, Markus F, Fichtner-Feigl, Stefan, Greten, Florian R · 2025 · Gut
  23. Colorectal Cancer Immunotherapy: State of the Art and Future Directions
    Cornista, Alyssa Mauri, Giolito, Maria Virginia, Baker, Kristi, Hazime, Hajar, Dufait, Inès, Datta, Jashodeep, Khumukcham, Saratchandra Singh, De Ridder, Mark, Roper, Jatin, Abreu, Maria T. et al. · 2023 · Gastro Hep Advances
  24. The Therapeutic Landscape for KRAS-Mutated Colorectal Cancers
    Tria, Simon Manuel, Burge, Matthew E., Whitehall, Vicki L. J. · 2023 · Cancers
  25. KRAS Mutation Dictates the Cancer Immune Environment in Pancreatic Ductal Adenocarcinoma and Other Adenocarcinomas
    Gu, Meichen, Gao, Yanli, Chang, Pengyu · 2021 · Cancers
  26. Development and validation of a gene signature classifier for consensus molecular subtyping of colorectal carcinoma in a CLIA-certified setting
    Morris, Jeffrey S., Luthra, Rajyalakshmi, Liu, Yusha, Duose, Dzifa Y., Lee, Wonyul, Reddy, Neelima G., Windham, Justin, Chen, Huiqin, Tong, Zhimin, Zhang, Baili et al. · 2021 · Clinical Cancer Research
  27. AKT3 expression in mesenchymal colorectal cancer cells drives growth and is associated with epithelial-mesenchymal transition
    Buikhuisen, Joyce Y., Gomez Barila, Patricia M., Torang, Arezo, Dekker, Daniëlle, de Jong, Joan H., Cameron, Kate, Vitale, Sara, Stassi, Giorgio, van Hooff, Sander R., Castro, Mauro A. A. et al. · 2021 · Cancers
  28. Consensus molecular subtype 4 (CMS4)-targeted therapy in primary colon cancer: a proof-of-concept study
    Peters, Niek A., Constantinides, Alexander, Ubink, Inge, van Kuik, Joyce, Bloemendal, Haiko J., van Dodewaard, Joyce M., Brink, Menno A., Schwartz, Thijs P., Lolkema, Martijn P.J.K., Lacle, Miangela M. et al. · 2022 · Frontiers in Oncology
  29. Fibroblast activation protein identifies consensus molecular subtype 4 in colorectal cancer and allows its detection by 68Ga-FAPI-PET imaging
    Strating, Esther, Wassenaar, Emma, Verhagen, Mathijs, Rauwerdink, Paulien, van Schelven, Susanne, de Hingh, Ignace, Rinkes, Inne Borel, Boerma, Djamila, Witkamp, Arjen, Lacle, Miangela et al. · 2022 · British Journal of Cancer
  30. Dark force rising: Reawakening and targeting of fetal-like stem cells in colorectal cancer
    Fey, Sigrid K., Vaquero-Siguero, Nuria, Jackstadt, Rene · 2024 · Cell Reports
  31. Computational estimation of quality and clinical relevance of cancer cell lines
    Trastulla, Lucia, Noorbakhsh, Javad, Vazquez, Francisca, McFarland, James, Iorio, Francesco · 2022 · Molecular Systems Biology
  32. Associations of non-pedunculated T1 colorectal adenocarcinoma outcome with consensus molecular subtypes, immunoscore, and microsatellite status: a multicenter case-cohort study
    Haasnoot, Krijn J.C., Backes, Yara, Moons, Leon M.G., Kranenburg, Onno, Trinh, Anne, Vermeulen, Louis, Noë, Michaël, Tuynman, Jurriaan B., van Lent, Anja U.G., van Ginneken, Rosaline et al. · 2020 · Modern Pathology
  33. Results from the UNITED study: a multicenter study validating the prognostic effect of the tumor–stroma ratio in colon cancer
    Polack, M., Smit, M.A., van Pelt, G.W., Roodvoets, A.G.H., Meershoek-Klein Kranenbarg, E., Putter, H., Gelderblom, H., Crobach, A.S.L.P., Terpstra, V., Petrushevska, G. et al. · 2024 · ESMO Open
  34. Alternative splicing downstream of EMT enhances phenotypic plasticity and malignant behavior in colon cancer
    Xu, Tong, Verhagen, Mathijs, Joosten, Rosalie, Sun, Wenjie, Sacchetti, Andrea, Munoz Sagredo, Leonel, Orian-Rousseau, Véronique, Fodde, Riccardo · 2022 · eLife
  35. Dual blockade of macropinocytosis and asparagine bioavailability shows synergistic anti-tumor effects on KRAS-mutant colorectal cancer
    Hanada, Keita, Kawada, Kenji, Nishikawa, Gen, Toda, Kosuke, Maekawa, Hisatsugu, Nishikawa, Yasuyo, Masui, Hideyuki, Hirata, Wataru, Okamoto, Michio, Kiyasu, Yoshiyuki et al. · 2021 · Cancer Letters
  36. Combinatorial treatment with statins and niclosamide prevents CRC dissemination by unhinging the MACC1-β-catenin-S100A4 axis of metastasis
    Kortüm, Benedikt, Radhakrishnan, Harikrishnan, Zincke, Fabian, Sachse, Christoph, Burock, Susen, Keilholz, Ulrich, Dahlmann, Mathias, Walther, Wolfgang, Dittmar, Gunnar, Kobelt, Dennis et al. · 2022 · Oncogene
  37. Interconnectivity between molecular subtypes and tumor stage in colorectal cancer
    Coebergh van den Braak, R. R. J., ten Hoorn, S., Sieuwerts, A. M., Tuynman, J. B., Smid, M., Wilting, S. M., Martens, J. W. M., Punt, C. J. A., Foekens, J. A., Medema, J. P. et al. · 2020 · BMC Cancer
  38. Downregulation of mitochondrial complex I induces ROS production in colorectal cancer subtypes that differently controls migration
    Bastin, Jean, Sroussi, Marine, Nemazanyy, Ivan, Laurent-Puig, Pierre, Mouillet-Richard, Sophie, Djouadi, Fatima · 2023 · Journal of Translational Medicine
  39. PU.1-driven Th9 Cells Promote Colorectal Cancer in Experimental Colitis Models Through Il-6 Effects in Intestinal Epithelial Cells
    Gerlach, Katharina, Popp, Vanessa, Wirtz, Stefan, Al-Saifi, Ragheed, Gonzalez Acera, Miguel, Atreya, Raja, Dregelies, Theresa, Vieth, Michael, Fichtner-Feigl, Stefan, McKenzie, Andrew N J et al. · 2022 · Journal of Crohn's and Colitis
  40. An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy
    Yang, Mingli, Davis, Thomas B., Pflieger, Lance, Nebozhyn, Michael V., Loboda, Andrey, Wang, Heiman, Schell, Michael J., Thota, Ramya, Pledger, W. Jack, Yeatman, Timothy J. · 2022 · BMC Cancer
  41. Oncogenic KRAS creates an aspartate metabolism signature in colorectal cancer cells
    Doubleday, Peter F., Fornelli, Luca, Ntai, Ioanna, Kelleher, Neil L. · 2021 · The FEBS Journal
  42. Prognostic value of the PrP <sup>C</sup> -ILK-IDO1 axis in the mesenchymal colorectal cancer subtype
    Ghazi, Alexandre, Le Corre, Delphine, Pilati, Camilla, Taieb, Julien, Aparicio, Thomas, Didelot, Audrey, Dedhar, Shoukat, Mulot, Claire, Le Malicot, Karine, Djouadi, Fatima et al. · 2021 · OncoImmunology
  43. Differential Radiographic Appearance of<i>BRAF</i>V600E–Mutant Metastatic Colorectal Cancer in Patients Matched by Primary Tumor Location
    Atreya, Chloe E., Greene, Claire, McWhirter, Ryan M., Ikram, Nabia S., Allen, I. Elaine, Van Loon, Katherine, Venook, Alan P., Yeh, Benjamin M., Behr, Spencer C. · 2016 · Journal of the National Comprehensive Cancer Network
  44. BRAF Inhibitors in Metastatic Colorectal Cancer and Mechanisms of Resistance: A Review of the Literature
    Guerrero, Patricia, Albarrán, Víctor, San Román, María, González-Merino, Carlos, García de Quevedo, Coral, Moreno, Jaime, Calvo, Juan Carlos, González, Guillermo, Orejana, Inmaculada, Chamorro, Jesús et al. · 2023 · Cancers
  45. Incorporating Intratumoral Heterogeneity into Weakly-Supervised Deep Learning Models via Variance Pooling
    Carmichael, Iain, Song, Andrew H., Chen, Richard J., Williamson, Drew F. K., Chen, Tiffany Y., Mahmood, Faisal · 2022 · Lecture Notes in Computer Science
  46. Molecular subtype-specific responses of colon cancer cells to the SMAC mimetic Birinapant
    Fichtner, Michael, Bozkurt, Emir, Salvucci, Manuela, McCann, Christopher, McAllister, Katherine A., Halang, Luise, Düssmann, Heiko, Kinsella, Sinéad, Crawford, Nyree, Sessler, Tamas et al. · 2020 · Cell Death &amp; Disease
  47. Notch receptor/ligand diversity: contribution to colorectal cancer stem cell heterogeneity
    Brisset, Morgan, Mehlen, Patrick, Meurette, Olivier, Hollande, Frédéric · 2023 · Frontiers in Cell and Developmental Biology
  48. KIT promotes tumor stroma formation and counteracts tumor-suppressive TGFβ signaling in colorectal cancer
    Küçükköse, Emre, Peters, Niek A., Ubink, Inge, van Keulen, Veere A. M., Daghighian, Roxanna, Verheem, André, Laoukili, Jamila, Kranenburg, Onno · 2022 · Cell Death &amp; Disease
  49. Activation of innate-adaptive immune machinery by poly(I:C) exposes a therapeutic vulnerability to prevent relapse in stroma-rich colon cancer
    Corry, Shania M, McCorry, Amy MB, Lannagan, Tamsin RM, Leonard, Niamh A, Fisher, Natalie C, Byrne, Ryan M, Tsantoulis, Petros, Cortes-Lavaud, Xabier, Amirkhah, Raheleh, Redmond, Keara L et al. · 2022 · Gut
  50. Recent Advances in Our Knowledge of mCRC Tumor Biology and Genetics: A Focus on Targeted Therapy Development
    Gmeiner, William H · 2021 · OncoTargets and Therapy
  51. KCML: a machine-learning framework for inference of multi-scale gene functions from genetic perturbation screens
    Sailem, Heba Z, Rittscher, Jens, Pelkmans, Lucas · 2020 · Molecular Systems Biology
  52. Colorectal Cancer-Associated Smad4 R361 Hotspot Mutations Boost Wnt/β-Catenin Signaling through Enhanced Smad4-LEF1 Binding
    Lanauze, Claudia B., Sehgal, Priyanka, Hayer, Katharina, Torres-Diz, Manuel, Pippin, James A., Grant, Struan F.A., Thomas-Tikhonenko, Andrei · 2021 · Molecular Cancer Research
  53. Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in <i>RAS</i> Wild-Type Metastatic Colorectal Cancer (PanaMa, AIO KRK 0212)
    Stahler, Arndt, Hoppe, Beeke, Na, Il-Kang, Keilholz, Luisa, Müller, Lothar, Karthaus, Meinolf, Fruehauf, Stefan, Graeven, Ullrich, Fischer von Weikersthal, Ludwig, Goekkurt, Eray et al. · 2023 · Journal of Clinical Oncology
  54. A proof of concept for targeting the PrPC - Amyloid β peptide interaction in basal prostate cancer and mesenchymal colon cancer
    Mouillet-Richard, Sophie, Martin-Lannerée, Séverine, Le Corre, Delphine, Hirsch, Théo Z., Ghazi, Alexandre, Sroussi, Marine, Pilati, Camilla, de Reyniès, Aurélien, Djouadi, Fatima, Vodovar, Nicolas et al. · 2022 · Oncogene
  55. Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in <i>KRASG12C</i> -mutant Colorectal Cancer
    Khawaja, Hajrah, Briggs, Rebecca, Latimer, Cheryl H., Rassel, Mustasin, Griffin, Daryl, Hanson, Lyndsey, Bardelli, Alberto, Di Nicolantonio, Frederica, McDade, Simon S., Scott, Christopher J. et al. · 2023 · Molecular Cancer Therapeutics
  56. Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients
    Alonso, Vicente, Escudero, Pilar, Fernández-Martos, Carlos, Salud, Antonia, Méndez, Miguel, Gallego, Javier, Rodriguez, Jose-R., Martín-Richard, Marta, Fernández-Plana, Julen, Manzano, Hermini et al. · 2018 · Neoplasia
  57. Functional Proteomic Profiling Analysis in Four Major Types of Gastrointestinal Cancers
    Wang, Yangyang, Gao, Xiaoguang, Wang, Jihan · 2023 · Biomolecules
  58. Differential Response and Resistance to KRAS-Targeted Therapy
    Liu, Zhaojin, Lenz, Heinz‐Josef, Yu, Jian, Zhang, Lin · 2025 · Molecular Carcinogenesis
  59. Consensus molecular subtype transition during progression of colorectal cancer
    van de Weerd, Simone, Torang, Arezo, Zwager, Liselotte W, Koelink, Pim J, Koster, Jan, Bastiaansen, Barbara AJ, Lammers, Veerle, Longobardi, Ciro, Roodhart, Jeanine ML, van Krieken, J Han et al. · 2023 · The Journal of Pathology
  60. EGFR Signaling in Colorectal Cancer: Novel Therapeutic Strategies, Predictive Biomarkers, and Counteracting Treatment Resistance
    Abbas, Noura, Mourad, Mohamad, Smaily, Hiba, Al Mahmasani, Layal, Shamseddine, Ali · 2026 · International Journal of Molecular Sciences
  61. Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer
    Arai, Hiroyuki, Millstein, Joshua, Loupakis, Fotios, Stintzing, Sebastian, Wang, Jingyuan, Battaglin, Francesca, Kawanishi, Natsuko, Jayachandran, Priya, Soni, Shivani, Zhang, Wu et al. · 2021 · European Journal of Cancer